Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Cellipont to provide technology transfer, process development, and cGMP manufacture of autologous MGB-001 TCR-T cell therapy program.
October 10, 2024
By: Kristin Brooks
Cellipont Bioservices, a cell therapy CDMO, and Mongoose Bio, a clinical-stage biopharma company pioneering next gen precision T-cell based therapies targeting solid cancers, signed an agreement for the technology transfer, process development, and cGMP manufacture of its autologous MGB-001 TCR-T cell therapy program. Mongoose Bio will leverage its antigen discovery pipeline and advanced memory T cell reprogramming technology to help address both common and rare solid tumors, delivering sustained immunoprotection. The platform integrates Generative Artificial Intelligence (Gen AI) to enhance the antigen discovery and T cell engineering processes, optimizing therapeutic efficacy and patient outcomes. MGB-001, Mongoose Bio’s lead asset is an epigenetically reprogrammed autologous TCR-T cell therapy directed against a target that is both highly immunogenic and broadly expressed in many solid tumors. Unlike other TCRs on the market or in development, ID/validation of this TCR epitope was rigorously selected from among an unbiased pool of 1000s of well-curated MHC-eluted peptides, empirically validated, and clinically annotated to target pan-cancers. This therapy is built on 17 years of work by founder Dr. Cassian Yee at his lab at the University of Texas MD Anderson Cancer Center (MDACC). “We’re pleased to be partnering with Mongoose Bio on their MGB-001 TCR-T Cell Therapy program. “We look forward to collaborating and working with their team to deliver this novel cell therapy to cancer patients,” said Mike O’Mara, COO of Cellipont Bioservices. “Cellipont is a strong partner for us and has excellent manufacturing capabilities to support advancing our lead candidate MGB-001 into the clinic,” said Neil Warma, President and CEO of Mongoose Bio. “Our TCR-T therapies have the potential to transform the treatment of cancer and with Cellipont’s team of experts on board, we are on target to bring this very promising therapy to patients who have failed approved, front-line therapies in multiple tumor indications.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !